Syntonix Pharmaceuticals, Inc.

Dyax Corporation

Bioverativ Therapeutics Inc.

Biogen Hemophilia Inc.

James Stattel

Alan J Bitonti

Robert Charles Ladner

Aaron Sato

Clive R Wood

Kevin McDonnell

Jennifer A Dumont

Christopher TenHoor

Arumugam Muruganandam

Liming Liu

Robert T Peters

Adam Robert Mezo

Susan C Low

Malini Viswanathan

Daniel S Rivera

Kevin Mcdonnell

Clive Wood

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Fc receptor binding proteins

The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

Immunoglobulin chimeric monomer-dimer hybrids

Growing community of inventors

Hagerstown, MD, United States of America

James Stattel